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OBJECTIVE—Chemerin is a recently discovered hepatoadipo-
kine that regulates adipocyte differentiation as well as chemo-
taxis and activation of dendritic cells and macrophages.
Chemerin was reported to modulate insulin sensitivity in adipo-
cytes and skeletal muscle cells in vitro and to exacerbate glucose
intolerance in several mouse models in vivo. In humans,
chemerin was shown to be associated with multiple components
of the metabolic syndrome including BMI, triglycerides, HDL
cholesterol, and hypertension. This study aimed to examine the
effect of chemerin on weight, glucose and lipid metabolism, as
well as atherosclerosis in vivo.
RESEARCH DESIGN AND METHODS—We used recombi-
nant adeno-associated virus to express human chemerin in LDL
receptor knockout mice on high-fat diet.
RESULTS—Expression of chemerin did not signiﬁcantly alter
weight, lipid levels, and extent of atherosclerosis. Chemerin,
however, signiﬁcantly increased glucose levels during the intra-
peritoneal glucose tolerance test without affecting endogenous
insulin levels and the insulin tolerance test. Chemerin reduced
insulin-stimulated Akt1 phosphorylation and activation of
5AMP-activated protein kinase (AMPK) in the skeletal muscle,
but had no effect on Akt phosphorylation and insulin-stimulated
AMPK activation in the liver and gonadal adipose tissue.
CONCLUSIONS—Chemerin induces insulin resistance in the
skeletal muscle in vivo. Chemerin is involved in the cross talk
between liver, adipose tissue, and skeletal muscle. Diabetes 59:
2898–2903, 2010
C
hemerin was initially described in 2003 as a
novel chemoattractant protein (1) that, upon
enzymatic proteolysis, modulates chemotaxis
and activation of dendritic cells and macro-
phages through distinct G protein-coupled receptors such
as CMKLR1, GPR1, and CCRL2 (2–4). More recently,
chemerin was reported as a hepatoadipokine that regu-
lates adipocyte differentiation in an autocrine/paracrine
manner via CMKLR1 and modulates the expression of
adipocyte genes involved in glucose and lipid homeostasis
(5,6). Conﬂicting data exist regarding the effect of
chemerin on insulin signaling in adipocytes in vitro.
Kralisch et al. (7) demonstrated that chemerin downregu-
lated insulin-stimulated glucose uptake in 3T3-L1 adipo-
cytes, while Takahasi et al. (8) reported the opposite. In
skeletal muscle cells, chemerin was shown to impair
insulin signaling and glucose uptake, a process partially
mediated by activation of the extracellular signal–regu-
lated kinases-1/2 (9). In humans, chemerin correlated with
systemic markers of inﬂammation such as high-sensitivity
C-reactive protein, interleukin-6, and tumor necrosis fac-
tor- and was associated with components of the meta-
bolic syndrome including BMI, triglycerides, HDL
cholesterol, and hypertension in different populations
(5,10–13). In morbidly obese patients undergoing bariatric
surgery, weight loss was associated with improvement of
various metabolic parameters and a sustained reduction of
chemerin levels (14,15). Taken together, available data
suggest that chemerin may play a role in glucose and lipid
metabolism as well as inﬂammation. Surprisingly little
data, however, are currently available about the potential
effects of chemerin on the regulation of these parameters
in vivo.
Recently, Ernst et al. (16) reported that acute adminis-
tration of recombinant human chemerin exacerbated glu-
cose intolerance, lowered serum insulin levels, and
decreased tissue glucose uptake in ob/ob, db/db, and
diet-induced obese (DIO) but not in normoglycemic wild-
type mice. As acute injection of chemerin may not reﬂect
the effect of chronically elevated chemerin levels seen in
obesity, we designed the present study to investigate the
impact of long-term chemerin overexpression on body
weight, glucose and lipid metabolism, as well as athero-
sclerosis in LDL receptor knockout (LDLRKO) mice on
a high-fat diet (HFD). As human chemerin fully binds to
and activates murine CMKLR1 (17), we expressed hu-
man chemerin using a recombinant adeno-associated
virus (AAV)-based vector in this well-established mouse
model of diet-induced insulin resistance, dyslipidemia,
and atherosclerosis.
RESEARCH DESIGN AND METHODS
Generation of recombinant adeno-associated viral constructs. All con-
structs were expressed under control of the thyroxine-binding globulin
promoter (18,19). Transgenes were full-length human chemerin (pre-
prochemerin, aa 1–163) and -galactosidase (LacZ) as control. To produce
AAV vectors encapsidated in an AAV8 capsid (AAV2.8), a pseudotyping
strategy was performed. Vectors (AAV.chemerin, AAV.lacZ) were puriﬁed
From the
1Department of Internal Medicine II, University of Munich, Munich,
Germany; and the
2Department of Internal Medicine I, University of Munich,
Munich, Germany.
Corresponding author: Uli C. Broedl, uli.broedl@med.uni-muenchen.de.
Received 13 March 2010 and accepted 30 July 2010. Published ahead of print
at http://diabetes.diabetesjournals.org on 9 August 2010. DOI: 10.2337/
db10-0362.
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
BRIEF REPORT
2898 DIABETES, VOL. 59, NOVEMBER 2010 diabetes.diabetesjournals.orgusing a standard cesium sedimentation method, and titers were determined
via TaqMan analysis using probes and primers targeting the bovine GH
poly(A) region of the vectors (18,19).
Animal studies. Male LDLRKO (B6.12957-LDLr
tm1Her/J) mice were obtained
from Charles River Laboratories (Sulzfeld, Germany). Mice (5 weeks of age)
were injected intravenously via the tail vein with 1  10
13 particles of
AAV.chemerin or AAV.lacZ. LDLRKO mice (n  13 per group) were kept on a
HFD (0.21% cholesterol, 21% butterfat; ssniff, Soest, Germany) for 16 weeks.
After 12 h of overnight fasting, blood was drawn before and several time
points after virus injection. The study was approved by the District Govern-
ment of Upper Bavaria.
The intraperitoneal glucose tolerance test (ipGTT) and the insulin toler-
ance test (ITT) were performed 12 and 14 weeks after AAV injection,
respectively (detailed description in the supplement available online at
http://diabetes.diabetesjournals.org/cgi/content/full/db10-0362/DC1).
At the end of the study (16 weeks after injection), mice (n  12 per group;
one death per group during the study) were injected intraperitoneally with
insulin (n  6 per group) (0.02 units/g body weight) or saline (n  6) to
determine protein levels and phosphorylation of Akt1 and 5AMP-activated
protein kinase (AMPK)-. Mice were killed 15 min after injection and organs
were harvested. Liver, skeletal muscle, and gonadal adipose tissue were
freeze-clamped in liquid nitrogen in situ and stored at 80°C for further
analysis. Aortas of LDLRKO mice were harvested for en face quantiﬁcation of
atherosclerotic lesions.
Blood sample assays. Human and murine serum chemerin levels were
determined using commercially available enzyme-linked immunosorbent as-
says (ELISAs) (R&D Systems, Wiesbaden, Germany). Plasma insulin levels
were measured with an ultrasensitive insulin immunoassay (Alpco, Salem,
MA). Serum total cholesterol, triglyceride, and HDL cholesterol levels were
measured enzymatically on an Alcyon 300 analyzer (Abbott GmbH, Wiesba-
den, Germany) using commercial reagents (Diasys, Holzheim, Germany).
Analysis of mRNA expression. Total RNA was extracted as previously
described (19). Real-time PCR was performed using the Realplex
4 Master-
cycler (Eppendorf, Hamburg, Germany). Expression levels of
genes of interest were determined using the Assays-On-Demand Taq-
Man primers and probes (Applied Biosystems, Carlsbad, CA) according
to the manufacturer’s instructions (supplemental data in the online
appendix).
Chemerin expression. One l of murine and human serum samples were
subjected to 10% BisTris gel and transferred to a polyvinylidene ﬂuoride
(PVDF) membrane (Immobilon-P, Zefa-Laborservice, Germany). Human
chemerin was detected with goat anti-human chemerin antibody (concentra-
tion 1:1,000; R&D Systems, Wiesbaden, Germany) and peroxidase-conjugated
AfﬁniPureRabbit anti-goat IgG (HL) (concentration 1:10.000; Jackson Immu-
noResearch, Baltimore, MD) as the secondary antibody.
Insulin signaling and activation of AMPK-. Liver, skeletal muscle, and
adipose tissue samples were homogenized in radioimmunoprecipitation
assay-buffer (50 mmol/l Tris-HCl, pH 7.4; 1% NP-40; 0,25% Na-deoxycholate;
150 mmol/l NaCl; 1 mmol/l EDTA; 1 mmol/l phenylmethylsulfonyl ﬂuoride;
1 g/ml of each aprotinin, leupeptin, pepstatin; 1 mmol/l Na3VO4; 1 mmol/l
NaF), and lysates were subjected to 10% BisTris gel and transferred to
PVDF membrane (Immobilon-P; Zefa-Laborservice, Germany). Anti Akt1
(C73H10) (concentration 1:1,000), phospho-Akt (Thr308) (C31E5) (concen-
tration 1:1,000), AMPK- (23A3) (concentration 1:1,000), phospho-AMPK-
(Thr172) (D79.5E) (concentration 1:1,000), and anti-rabbit IgG horseradish
peroxidase-linked antibodies (concentration 1:10.000) were obtained from
Cell Signaling (Danvers, MA). Anti-actin antibody was purchased from
Sigma (Sigma, St. Louis, MO).
Histological analysis. For the quantiﬁcation of the aortic plaques, the mouse
aorta was carefully harvested and stained with Sudan IV (Sigma, Germany) as
previously described (18,19). The extent of the lesion area was determined
using Nikon Nis Elements D3.0 (Nikon, Du ¨sseldorf, Germany). Data are
reported as the percentage of the aortic surface covered by lesions (total
surface area of the atherosclerotic lesions divided by the total surface area of
the aorta).
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FIG. 1. A: Western blot analysis of chemerin expression in serum samples of LDLRKO mice 16 weeks after injection with 1  10
13 particles of
AAV.lacZ or AAV.chemerin and a healthy human volunteer. B: Expression of chemerin in LDLRKO mice 16 weeks after injection with 1  10
13
particles of AAV.lacZ or AAV.chemerin (n  12 per group) and in 3 healthy human volunteers as assessed by ELISA. C: Murine chemerin levels
in LDLRKO mice 16 weeks after injection with 1  10
13 particles of AAV.lacZ or AAV.chemerin (n  12 per group) as assessed by ELISA.
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data was performed using the unpaired Student t test. Statistical signiﬁcance
for all comparisons was assigned at P 
 0.05.
RESULTS
To examine the effect of chemerin expression on body
weight, glucose and lipid metabolism, as well as athero-
sclerosis in vivo, LDLRKO mice on HFD were injected
with 1  10
13 particles of AAV.chemerin or control (AAV.
lacZ). Injection of AAV.chemerin resulted in speciﬁc and
sustained chemerin expression over the course of the
study with serum levels comparable with those seen in
healthy human volunteers (Fig. 1A and B). Expression of
human chemerin did not alter murine chemerin serum
levels (Fig. 1C).
Mice injected with AAV.chemerin or AAV.lacZ had a
similar change in body weight over the 16-week study
period (supplemental Fig. 1, found in the online appen-
dix). Compared with control mice, chemerin-expressing
mice showed signiﬁcantly increased glucose levels dur-
ing both the ipGTT (without affecting endogenous insu-
lin levels) and the ITT (Fig. 2), indicating that
overexpression of human chemerin induces insulin re-
sistance in LDLRKO mice. To determine whether ex-
pression of chemerin resulted in a tissue-speciﬁc
pattern of insulin resistance, insulin signaling was ex-
amined in liver, adipose tissue, and skeletal muscle.
Expression of chemerin substantially reduced insulin-
stimulated Akt1 phosphorylation and AMPK- activa-
tion in the skeletal muscle (Fig. 3). In contrast, mice
injected with AAV.chemerin showed no effect on basal
and insulin-stimulated hepatic Akt1 phosphorylation,
AMPK- activation, and the mRNA expression of the
gluconeogenic enzymes G6P and PEPCK (supplemental
Fig. 2, found in the online appendix). In gonadal adipose
tissue, expression of chemerin slightly decreased phos-
pho-AMPK- levels in the absence of insulin but did not
alter insulin-stimulated AMPK- activation and Akt1
signaling (supplemental Fig. 3, found in the online
appendix). In conclusion, expression of chemerin in-
duced glucose intolerance via induction of insulin resis-
tance in the skeletal muscle.
Mice-expressing chemerin did not show signiﬁcantly
altered total cholesterol, triglyceride, HDL cholesterol,
and non-HDL cholesterol levels compared with controls
(supplemental Fig. 4, found in the online appendix). Like-
wise, expression of chemerin did not change the mean
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FIG. 2. Effect of chemerin on glucose (A) and insulin (B) levels during
the ipGTT in LDLRKO mice 12 weeks after injection with AAV.lacZ
(black triangle) or AAV.chemerin (white square) (n  10 per group).
Effect of chemerin on glucose levels during the ITT (C) in LDLRKO
mice 14 weeks after injection with AAV.lacZ (black triangle) or
AAV.chemerin (white square) (n  10 per group). *P < 0.05, **P 
0.01.
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analysis of the entire aorta (Fig. 4).
DISCUSSION
Our study aimed to determine the effect of human
chemerin on weight, glucose and lipid metabolism, as well
as atherosclerosis in vivo in LDLRKO mice on HFD. We
demonstrated that expression of chemerin with serum
levels comparable with those seen in healthy human
volunteers induced insulin resistance in the skeletal mus-
cle with increased glucose levels during both the ipGTT
and the ITT. Expression of chemerin, however, did not
signiﬁcantly alter weight, lipid levels, and extent of ath-
erosclerotic lesion area.
Ernst et al. (16) reported that acute administration of
recombinant human chemerin exacerbated glucose intol-
erance and lowered serum insulin levels in ob/ob and db/db
mice but had no effect on glucose tolerance in wild-type
mice on chow diet. Chemerin injection of DIO mice also
resulted in impaired glucose tolerance but (except for the
2-h time point) did not reduce insulin levels during GTT.
Chemerin signiﬁcantly decreased liver but not skeletal
muscle glucose uptake in db/db mice. Consistent with
Ernst et al. (16), long-term expression of human chemerin
in our diet-induced mouse model of insulin resistance and
atherosclerosis resulted in glucose intolerance without
altering insulin levels. We did not assess the effect of
chemerin on glucose uptake in different tissues. However,
given the results of the present study, we would have
expected decreased glucose uptake in the skeletal muscle
consistent with data from Sell et al. (9) demonstrating that
chemerin impaired insulin signaling and glucose uptake in
skeletal muscle cells in vitro. Unfortunately, Ernst et al.
(16) did not report the effect of acute chemerin adminis-
tration on glucose uptake in DIO mice. Further studies,
including clamp techniques, are necessary to better char-
acterize the effect of chemerin on glucose metabolism in
vivo and to address the mechanism by which chemerin
reduced insulin-stimulated Akt1 phosphorylation and
AMPK- activation in the skeletal muscle. In vitro, Sell et
al. (9) identiﬁed activation of p38 MAP kinase, extracellu-
lar signal–regulated kinases-1/2, and p56 as potential
mechanisms that might mediate the effect of chemerin on
insulin resistance in skeletal muscle cells.
In contrast to epidemiological data (5,12,13), chemerin
had no signiﬁcant effect on triglyceride and HDL choles-
terol levels in our study. Studies in mice with a more
human-like lipoprotein metabolism (e.g., APOE*3-Leiden.
CETP transgenic mice) may be required to reproduce the
lipid phenotype seen in humans.
Lack of chemerin on the atherosclerotic lesion area
does not contradict previous studies demonstrating that
chemerin modulates activation of immune cells in in-
ﬂamed tissues of patients with skin disorders (20,21) or
mouse models of peritonitis and lung disease (3,17). One
could speculate that chemerin may affect early atheroscle-
rotic plaque development and/or plaque morphology
rather than extent of atherosclerotic lesion area. In pa-
tients with stable chest pain, however, chemerin was not
associated with coronary atherosclerotic plaque morphol-
ogy as determined by computed tomography-angiography
(12).
Chemerin is synthesized as a secreted precursor,
prochemerin, which is poorly active on the chemerin
receptor CMKLR1 (1). Prochemerin can be rapidly con-
verted into inactive, proinﬂammatory, or anti-inﬂamma-
tory chemerin variants by proteolytic removal of carboxy-
terminal peptides mediated by distinct proteases of the
coagulation and inﬂammation cascades (3,22–24). Unfor-
tunately, the antibodies used in our study for Western blot
analysis, human and murine chemerin ELISAs, detect
prochemerin, chemerin, and other proteolytically pro-
cessed forms but do not allow us to distinguish between
these peptides. Since distinct chemerin forms differ sub-
stantially in their bioactivity, the signiﬁcance for total
chemerin assessment is limited thus complicating the
interpretation of our results. It is reasonable to speculate
that since both human and murine chemerin activate the
murine chemerin receptor CMKLR1 (17), overall increased
chemerin levels resulted in glucose intolerance and insulin
resistance in the skeletal muscle of LDLRKO mice on HFD.
However, it is also conceivable that expression of
D
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FIG. 3. Effect of chemerin on basal and insulin-stimulated Akt1 phosphorylation (pAkt1) (A, C) and AMPK- phosphorylation (pAMPK-)( B, D)
in the skeletal muscle of LDLRKO mice injected with AAV.lacZ or AAV.chemerin (data are representative for n  6 per group).
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ing both murine and human chemerin bioactivity.
In summary, we determined in this present study the
effect of human chemerin on weight, glucose and lipid
metabolism, as well as atherosclerosis in vivo. We demon-
strated that expression of chemerin induced insulin resis-
tance in the skeletal muscle of LDLRKO mice on HFD.
Expression of chemerin, however, did not signiﬁcantly
alter weight, lipid levels, and extent of atherosclerotic
lesion area.
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